Abiopharma

🔍 HAGEMANN ROBERT (Executive)

Company: ZIMMER BIOMET HOLDINGS, INC. (ZBH)

Report Date: 2026-03-31

Detailed Transactions and Holdings:

• Acquired 309 shares of Phantom Stock Units at $89.08 per share (Derivative)
  Date: 2026-03-31 | Code: A | equity_swap_involved: 0 | shares_owned_after: 31,982.84 | transaction_form_type: 4 | Footnotes: F1, F2, F3, F3, F4

Footnotes:

• F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
• F2: The Conversion or Exercise Price of Derivative Security is 1-for-1.
• F3: Units are to be settled in cash in five annual installments commencing within sixty days after the end of the calendar year in which the cessation of the reporting person's service as a Director occurs.
• F4: Includes 87.178 phantom stock units accrued on January 30, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.